Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
BACKGROUND
Duloxetine is indicated for patients with a variety of conditions, and some of these patients may have mild to moderate degrees of renal impairment. Renal impairment may affect the pharmacokinetics of a drug by causing changes in absorption, distribution, protein binding, renal excretion or nonrenal clearance. As duloxetine is highly bound to plasma proteins and its metabolites are renally excreted, it is prudent to evaluate the effect of renal insufficiency on exposure to duloxetine and its metabolites in the systemic circulation.


OBJECTIVE
The aim of this study was to evaluate the effects of varying degrees of renal impairment on duloxetine pharmacokinetics in a single-dose phase I study and using pooled steady-state pharmacokinetic data from phase II/III trials.


METHODS
In the phase I study, a single oral dose of duloxetine 60 mg was given to 12 subjects with end-stage renal disease (ESRD) and 12 matched healthy control subjects. In the phase II/III trials (n = 463 patients), duloxetine 20-60 mg was given as once- or twice-daily doses. Duloxetine and metabolite concentrations in plasma were determined using liquid chromatography with tandem mass spectrometry. Noncompartmental methods (phase I: duloxetine and its metabolites) and population modelling methods (phase II/III: duloxetine) were used to analyse the pharmacokinetic data.


RESULTS
The maximum plasma concentration (C(max)) and the area under the plasma concentration-time curve (AUC) of duloxetine were approximately 2-fold higher in subjects with ESRD than in healthy subjects, which appeared to reflect an increase in oral bioavailability. The C(max) and AUC of two major inactive conjugated metabolites were as much as 2- and 9-fold higher, respectively, reflecting reduced renal clearance of these metabolites. Population pharmacokinetic results indicated that mild or moderate renal impairment, assessed by creatinine clearance (CL(CR)) calculated according to the Cockcroft-Gault formula, did not have a statistically significant effect on pharmacokinetic parameters of duloxetine. Values for the apparent total body clearance of duloxetine from plasma after oral administration (CL/F) in subjects with ESRD were similar to CL/F values in patients with normal renal function or with mild or moderate renal impairment.


CONCLUSIONS
Dose adjustments for duloxetine are not necessary for patients with mild or moderate renal impairment (CL(CR) > or =30 mL/min). For patients with ESRD or severe renal impairment (CL(CR) <30 mL/min), exposures of duloxetine and its metabolites are expected to increase; therefore, duloxetine is not generally recommended for these patients.
Lobo
Evelyn D
ED
Eli Lilly and Company, Drug Disposition, Global Pharmacokinetic/Pharmacodynamic Trial Simulation, Indianapolis, Indiana 46285-0724, USA. loboev@lilly.com
Heathman
Michael
M
Kuan
Han-Yi
HY
Reddy
Shobha
S
O'Brien
Lisa
L
Gonzales
Celedon
C
Skinner
Michael
M
Knadler
Mary Pat
MP
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D013876:Thiophenes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*
D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
Br J Clin Pharmacol. 2007 Mar;63(3):310-4
17380590
Eur J Clin Pharmacol. 1998 Jan;53(5):361-7
9516038
Clin Pharmacokinet. 2009;48(3):189-97
19385712
Neurology. 2006 Oct 24;67(8):1411-20
17060567
Clin Pharmacokinet. 2008;47(3):191-202
18307373
J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53
17414226
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):582-9
17350901
BJOG. 2004 Mar;111(3):249-57
14961887
J Clin Psychiatry. 2003 Oct;64(10):1237-44
14658974
Clin Pharmacol Ther. 2003 Mar;73(3):170-7
12621382
J Pharmacol Exp Ther. 1995 Jan;272(1):177-83
7815331
Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6
15177457
Curr Med Res Opin. 2007 Jun;23(6):1245-52
17559726
Psychopharmacol Bull. 2002 Autumn;36(4):106-32
12858150
Pain. 2005 Jul;116(1-2):109-18
15927394
J Pharmacol Exp Ther. 1996 Apr;277(1):278-86
8613930
Acta Psychiatr Scand Suppl. 1997;391:7-13
9265946
Prim Care Companion J Clin Psychiatry. 2007;9(2):100-7
17607331
Neuropsychopharmacology. 1993 Jan;8(1):23-33
8424846
J Diabetes Complications. 2009 Sep-Oct;23(5):349-59
18768332
Br J Clin Pharmacol. 2004 Jan;57(1):54-61
14678340
Drug Metab Dispos. 2003 Sep;31(9):1142-50
12920170
Am J Kidney Dis. 2001 Oct;38(4 Suppl 4):S11-7
11602456
J Clin Pharmacol. 2000 Feb;40(2):161-7
10664922
Int J Clin Pharmacol Ther. 2005 Feb;43(2):78-84
15726876
BJU Int. 2008 Jul;102(2):214-8
18422764
Pain. 2005 Dec 15;119(1-3):5-15
16298061
J Clin Psychiatry. 2002 Mar;63(3):225-31
11926722
J Palliat Med. 2006 Feb;9(1):29-40
16430342
Curr Opin Investig Drugs. 2000 Sep;1(1):116-21
11249587
Clin Pharmacol Ther. 2008 Jun;83(6):898-903
18388866